To include your compound in the COVID-19 Resource Center, submit it here.

Prophage vitespen: Phase II data

A Phase II trial in 30 evaluable patients with recurrent high-grade GBM showed that Prophage Series G-200 led

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE